DE2353239A1 - Verfahren zur bestimmung der wirksamkeit von antiviralen mitteln und mittel zur durchfuehrung des verfahrens - Google Patents
Verfahren zur bestimmung der wirksamkeit von antiviralen mitteln und mittel zur durchfuehrung des verfahrensInfo
- Publication number
- DE2353239A1 DE2353239A1 DE19732353239 DE2353239A DE2353239A1 DE 2353239 A1 DE2353239 A1 DE 2353239A1 DE 19732353239 DE19732353239 DE 19732353239 DE 2353239 A DE2353239 A DE 2353239A DE 2353239 A1 DE2353239 A1 DE 2353239A1
- Authority
- DE
- Germany
- Prior art keywords
- interferon
- virus
- cells
- procedure
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 31
- 239000003443 antiviral agent Substances 0.000 title claims description 10
- 102000014150 Interferons Human genes 0.000 claims description 57
- 108010050904 Interferons Proteins 0.000 claims description 57
- 229940079322 interferon Drugs 0.000 claims description 57
- 241000700605 Viruses Species 0.000 claims description 32
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 27
- 230000000840 anti-viral effect Effects 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 101710088194 Dehydrogenase Proteins 0.000 claims description 5
- 102000003929 Transaminases Human genes 0.000 claims description 4
- 108090000340 Transaminases Proteins 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- SPYYZVSDULLIHD-UHFFFAOYSA-N OC(=O)CCCC(O)=O.OC(=O)CC(=O)C(O)=O Chemical compound OC(=O)CCCC(O)=O.OC(=O)CC(=O)C(O)=O SPYYZVSDULLIHD-UHFFFAOYSA-N 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 51
- 229940088598 enzyme Drugs 0.000 description 23
- 238000011534 incubation Methods 0.000 description 19
- 230000009385 viral infection Effects 0.000 description 14
- 239000012895 dilution Substances 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 230000006378 damage Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 241000711975 Vesicular stomatitis virus Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4912772A GB1443425A (en) | 1972-10-25 | 1972-10-25 | Interferon assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2353239A1 true DE2353239A1 (de) | 1974-05-09 |
Family
ID=10451245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732353239 Ceased DE2353239A1 (de) | 1972-10-25 | 1973-10-24 | Verfahren zur bestimmung der wirksamkeit von antiviralen mitteln und mittel zur durchfuehrung des verfahrens |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS49134398A (enExample) |
| CA (1) | CA1012044A (enExample) |
| DE (1) | DE2353239A1 (enExample) |
| FR (1) | FR2226073A5 (enExample) |
| GB (1) | GB1443425A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014839A1 (en) * | 1991-02-14 | 1992-09-03 | Imperial Cancer Research Technology Limited | Test method |
| US5494799A (en) * | 1986-03-06 | 1996-02-27 | Commonwealth Scientific & Industrial Research Organisation | In vitro assay for detecting cell-mediated immune responses |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675282A (en) * | 1984-07-06 | 1987-06-23 | Damon Biotech, Inc. | Assay for interferon epsilon |
-
1972
- 1972-10-25 GB GB4912772A patent/GB1443425A/en not_active Expired
-
1973
- 1973-10-24 JP JP11906273A patent/JPS49134398A/ja active Pending
- 1973-10-24 FR FR7337929A patent/FR2226073A5/fr not_active Expired
- 1973-10-24 DE DE19732353239 patent/DE2353239A1/de not_active Ceased
- 1973-10-24 CA CA184,112A patent/CA1012044A/en not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494799A (en) * | 1986-03-06 | 1996-02-27 | Commonwealth Scientific & Industrial Research Organisation | In vitro assay for detecting cell-mediated immune responses |
| WO1992014839A1 (en) * | 1991-02-14 | 1992-09-03 | Imperial Cancer Research Technology Limited | Test method |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6175573A (en) | 1975-04-24 |
| FR2226073A5 (enExample) | 1974-11-08 |
| JPS49134398A (enExample) | 1974-12-24 |
| GB1443425A (en) | 1976-07-21 |
| CA1012044A (en) | 1977-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Socransky et al. | Difficulties encountered in the search for the etiologic agents of destructive periodontal diseases | |
| Stenchever et al. | Chromosome breakage in users of marihuana | |
| DE69931892T2 (de) | Test auf Antibiotikumempfindlichkeit | |
| DE69323019T2 (de) | Verbesserter Nachweis von Mikroorganismen | |
| DE69624593T2 (de) | Verfahren zum nachweis von bakterien | |
| Forrester et al. | Microelectrophoresis of normal and transformed clones of hamster kidney fibroblasts | |
| DE2548963A1 (de) | Verfahren und mittel zur bestimmung der aktivitaet von creatinkinase-mb | |
| Abramsson-Zetterberg et al. | The micronucleus test in rat erythrocytes from bone marrow, spleen and peripheral blood: the response to low doses of ionizing radiation, cyclophosphamide and vincristine determined by flow cytometry | |
| Sisken et al. | Pulsed electromagnetic fields and normal chick development | |
| EP0433927B1 (de) | Mittel zur Verbesserung der Wiederfindung von Annexinen | |
| DE2353239A1 (de) | Verfahren zur bestimmung der wirksamkeit von antiviralen mitteln und mittel zur durchfuehrung des verfahrens | |
| EP0185335A2 (de) | Verfahren zum Nachweis des Vorliegens einer Allergie und zum spezifischen Nachweis des für die Allergie verantwortlichen Allergens | |
| Spicer et al. | Biochemistry of natural and amprolium‐induced polioencephalomalacia in sheep | |
| EP0435226B1 (de) | Phagozytose-Test | |
| Daniels | Studies on the effect of X-irradiation upon Pelomyxa carolinensis with special reference to nuclear division and plasmotomy | |
| DE69119576T2 (de) | Verfahren zur Abtrennung, Identifizierung und Quantifizierung von Isoenzymen und Isoformen der alkalischen Phosphatase | |
| McCoy et al. | The penetration of radioactive phosphorus into encysted Trichinella larvae | |
| Kendall et al. | 5-nucleotidase in the serum and synovial fluid of patients with rheumatoid disease | |
| Galanaud et al. | Sodium periodate-induced suppressor T cells of the human in vitro antibody response | |
| Quastel et al. | Interspecies differences in the inhibitory effect of ouabain on lymphocyte transformation | |
| Sato et al. | Urinary excretion of catecholamines and their metabolites in normotensive and hypertensive subjects | |
| DE1954728C3 (de) | Pufferlösung zur Verwendung in einem Hämagglutinationstest | |
| DE2555188C2 (de) | Verfahren zum Nachweis von Antigen oder Antikörper von infektiöser Hepatitis A in einer Probe | |
| Park et al. | Perinuclear microtubules in postnatal rat heart | |
| DE19505056C1 (de) | In vitro Kultivierung von pleomorphen Trypanosomenstämmen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8131 | Rejection |